ArticleMedicine2026
The causal impact of gut microbiota on allergic rhinitis mediated by cerebrospinal fluid metabolites: A study based on Mendelian randomization and mediation analysis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
In recent years, the role of gut microbiota (GM) in the pathogenesis of allergic diseases (ADs) has garnered increasing attention, yet the influence of the brain and its metabolites (such as cerebrospinal fluid [CSF] metabolites) remains unclear. This study aims to investigate whether GM mediates its effect on allergic rhinitis (AR) through CSF metabolites and to quantify this mediating effect, while systematically evaluating the causal relationships between brain functional networks/CSF metabolites and multiple ADs to elucidate the potential roles of brain-related factors in allergic mechanisms. Using large-scale genome-wide association study data, including GM (n = 7738), brain functional networks (n = 47,276), CSF metabolites (n = 291), and 7 categories of AD (Finnish R12 database), we applied Mendelian randomization (MR) for causal inference. Specifically, we performed: mediation MR to test the GM-CSF metabolites-AR pathway; and 2-sample MR to assess causal relationships between brain functional networks/CSF metabolites and ADs. Genetically predicted analyses revealed significant associations between GM and both CSF metabolites and AR. Mediation MR confirmed that Peptococcia abundance exerts a positive causal effect on AR (odds ratio [OR] = 1.55, 95% confidence interval [CI] = 1.23-1.95, P = .0002), which was partially mediated by CSF methyl succinoyl-carnitine levels, with a mediation proportion of 9.02%. Extended analyses indicated that CSF metabolites are positively associated with allergic contact dermatitis and pollen allergy: specifically, methyl succinoyl-carnitine levels correlated positively with pollen allergy, and indoleacetate levels with allergic contact dermatitis (both significant after false discovery rate correction). Brain functional network analyses showed allergic urticaria was negatively correlated with 9 functional networks, including the occipital-precuneus and postcentral gyrus. This study is the first, via MR, to demonstrate that GM may partially influence AR risk through CSF metabolites (e.g., methyl succinoyl-carnitine); concurrently, brain functional networks regulate specific ADs. These findings deepen understanding of the "gut-brain-immune" axis mechanism and provide new directions for future precise interventions targeting metabolites and neuroimmune pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.